Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 9/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24365679 | 0.76 | FGFR1 (0.47) | ROCK2FGFR1FGFR2AXLCHEK1 | |
| SCHEMBL24365178 | 0.76 | CLK1 (0.49) | TRPA1ROCK2FGFR1CHEK1ROCK1 | |
| SCHEMBL24363948 | 0.74 | TRPA1 (0.43) | TRPA1AXLROCK1 | |
| SCHEMBL24363950 | 0.74 | TRPA1 (0.43) | TRPA1AXLROCK1 | |
| SCHEMBL30470235 | 0.69 | PIK3C3 (0.41) | ROCK2FGFR1AXLCHEK1ROCK1 | |
| SCHEMBL24365204 | 0.69 | PIK3C3 (0.41) | ROCK2FGFR1AXLCHEK1ROCK1 | |
| SCHEMBL31145118 | 0.69 | TRPA1 (0.42) | TRPA1ROCK2FGFR1FGFR2TRPM8 | |
| SCHEMBL29347993 | 0.67 | NISCH (0.37) | — | |
| SCHEMBL14738406 | 0.66 | CHEK1 (0.56) | TRPA1ROCK2FGFR1FGFR2AXL | |
| SCHEMBL31145119 | 0.65 | MET (0.40) | TRPA1ROCK2FGFR1FGFR2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TRPA1 848/4885ROCK2 2430/4885FGFR1 1388/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | TRPA1 848/4885ROCK2 2430/4885FGFR1 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.